Access strategic financial leadership – from executive guidance to interim management – to navigate the unique complexities of life sciences companies.
Life science companies face unique financial and operational hurdles that require specialized experience. Extended development cycles can stretch 10-15 years with uncertain outcomes. Clinical trials require significant upfront investment with no immediate revenue. Regulatory compliance demands sophisticated financial reporting. Resource allocation decisions happen under extreme uncertainty, making it critical to allocate limited resources to high-value drug development programs.
Our team partners with founders, CEOs, boards, and investors to guide emerging and mid-sized companies through periods of growth and transition. We help businesses in sectors like diagnostics, pharmaceuticals, therapeutics, and medical devices navigate complex situations including M&A transactions, rapid growth and turnarounds.
Clinical operations: We help build relationships with external vendors, such as study investigators, CROs, and central labs, to maximize trial efficiency.
Go to market: We prepare you for commercial launch, including implementing ERP systems, establishing a chain of custody, and structuring financial statements.
Strategic planning: In today’s challenging environment, it’s critical to allocate limited resources to high-value drug development programs. We help you make those strategic decisions.
FP&A: Our focus is on multi-year planning that accounts for extended drug development life cycles.
Cash flow: We use scenario planning to manage limited cash flows and leverage clinical milestones to secure advantageous funding opportunities.
Financial support: We build strong relationships with your functional leads, C-suite, board members, and investors to support critical decisions, from internal hiring to external business development opportunities.
Interim CFO: We can serve as your interim CFO during a transition, working with your finance, accounting, and operations teams to ensure a seamless shift.
On February 20, 2026, the U.S. Supreme Court issued a significant trade ruling that affects businesses managing import costs, supply chain decisions, or cross-border sourcing. Here’s what you need to know.
Learn More
The Life Sciences Industry Outlook 2026 examines key trends shaping biotech, medtech, and pharma, from precision medicine and digital trials to funding, manufacturing, and regulatory change.
Learn More
Discover key licensing and tax planning strategies for emerging life sciences companies. Our professionals from BPM and Mayer Brown will cover R&D tax credits, transfer pricing, and international expansion to help you navigate complex challenges.
Learn More
When you work with BPM, you gain access to CFO-level financial leadership specifically designed for the complexities of life sciences. Our team understands the unique challenges of drug development timelines, regulatory requirements, and the critical importance of clinical milestones in securing funding and driving growth. Whether you’re navigating rapid expansion, preparing for commercial launch, or managing a crucial transition, we provide the strategic financial guidance that helps life sciences companies thrive.
Minimize risks and maximize value with in-depth evaluation of potential business deals.
Modernize finance from cost center to strategic advantage: Your finance transformation starts here.
